Calfactant - Biologic Drug Details

Summary for calfactant

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for calfactant

Recent Clinical Trials for calfactant

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Meriter Foundation	PHASE2
University of Wisconsin, Madison	PHASE2
Uludag University	PHASE4

See all calfactant clinical trials

Pharmacology for calfactant

Mechanism of Action	Surfactant Activity
Physiological Effect	Alveolar Surface Tension Reduction
Established Pharmacologic Class	Surfactant

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for calfactant Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for calfactant Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for calfactant Derived from Patent Text Search

No patents found based on company disclosures

Calfactant Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Calfactant?

Calfactant is a surfactant used in neonatal medicine to treat respiratory distress syndrome (RDS) in preterm infants. It is administered via intratracheal instillation and is derived from bovine lung extract. Its market relies on neonatal intensive care unit (NICU) demand, global birth rates of preterm infants, and competition from other surfactants.

Key Market Drivers

• Incidence of preterm birth: Approximately 10.6% of all live births globally in 2021, with higher prevalence in low- and middle-income countries.
• RDS prevalence: RDS affects 60-80% of infants born before 28 weeks’ gestation; roughly 1% of all live births.
• Clinical adoption: Calfactant markets on the basis of clinical guidelines favoring surfactant therapy for preterm neonates.
• Existing competitors: Poractant alfa (Curosurf), beractant (Survanta), and synthetic surfactants, leading to a competitive landscape.
• Healthcare spending: Growing neonatal care expenditure in emerging economies enhances market access.

Challenges

• Pricing pressures: Reimbursements for neonatal therapies are under scrutiny, affecting profit margins.
• Generic and biosimilars entry: Limited, but possible as patents expire or biosimilar pathways establish.
• Regulatory hurdles: Variability across countries delays market expansion.

Market Size and Growth (2022–2027)

The global neonatal surfactant market, which includes calfactant, is estimated at $400 million in 2022. It’s forecasted to grow at a compound annual growth rate (CAGR) of approximately 4.3% to reach around $540 million by 2027.

• North America: Dominates with a 55% share, driven by advanced NICU infrastructure.
• Europe: Second-largest market, with slow but steady growth.
• Asia-Pacific: Fastest growth (CAGR of 6%) due to rising neonatal care investments.

What Is the Financial Trajectory for Calfactant?

Revenue Trends

Calfactant sales are primarily propelled by hospital procurement contracts and clinical adoption in NICUs. Since its approval, revenues have been relatively stable but sensitive to market competition and pricing strategies.

• Historical revenue (2020–2022): Estimated at $25–$50 million annually for key operators (e.g., ModaTex, responsible for marketing).
• Pricing: Approximate average price per dose ranges from $200 to $400, depending on regional healthcare policies and volume discounts.
• Profitability: Margins are impacted by manufacturing costs and reimbursement rates.

Key Financial Influences

• Market penetration: Increased by gaining approval in newer markets such as China, India.
• Regulatory environment: Influences launch costs and time-to-market.
• Competition: Shifts in approvals of biosimilar surfactants could pressure pricing.

Outlook (2023–2030)

• Revenue growth: Expected to follow global neonatal surfactant trends, with an estimated CAGR of 4–6%, barring disruptive biosimilar entries.
• Investment in R&D: Companies may invest in synthetic or more cost-effective formulations, influencing future market share.
• Partnerships and licensing: Strategic collaborations could expand access and accelerate market penetration.

Financial Risks

• Regulatory delays can constrain revenue projections.
• Pricing reforms in healthcare systems may pressure profit margins.
• Emergence of biosimilar candidates could lead to price erosion.

What Are the Key Takeaways?

1. The calfactant market centers around neonatal RDS treatment in NICUs, with growth driven by preterm birth rates and healthcare infrastructure expansion.
2. The global neonatal surfactant market is projected to reach $540 million by 2027, growing at 4.3% annually.
3. Revenue stability depends on clinical adoption, regional market entry, and competitive dynamics.
4. The financial outlook benefits from emerging markets and strategic licensing but faces risks from biosimilar competition and healthcare policy shifts.
5. Investment focus should remain on market expansion, regulatory navigation, and cost optimization.

FAQs

1. Who manufactures calfactant?
   Currently licensed by ModaTex in the U.S., with other manufacturers supplying in different regions.

2. What are the main competitors to calfactant?
   Poractant alfa (Curosurf) and beractant (Survanta) dominate the market, with synthetic options emerging.

3. How does pricing vary across regions?
   In North America, prices average $200–$400 per dose; lower in emerging markets due to healthcare subsidies.

4. What are regulatory hurdles impacting calfactant?
   Approvals depend on regional drug authorities (FDA, EMA, CFDA), with timelines affected by local clinical data requirements.

5. What is the outlook for biosimilars?
   Biosimilar surfactants could enter the market within the next 5–7 years, intensifying competition and affecting pricing.

---

Citations

[1] MarketsandMarkets, "Neonatal Surfactants Market," 2022.
[2] World Health Organization, "Preterm Birth," 2023.
[3] EvaluatePharma, "Neonatal Market Overview," 2023.
[4] US FDA, "Regulatory Pathways for Biologics," 2022.